Baylor St. Luke’s Continues to be an Early Adopter of Innovations in Aneurysm Treatment
Last year, Baylor St. Luke’s Medical Center was the first in Texas to use the PulseRider, a neurovascular device used to treat patients with wide-necked bifurcation aneurysms. One year later, advancements have been made in the area and the hospital is again one of the first to begin using WEB, a new FDA approved device to treat aneurysms. After a series of cases, Peter Kan, M.D., neurosurgeon at Baylor St. Luke’s, became the first neurointerventionalist to be certified in Texas, Louisiana, Mississippi, and Oklahoma.
The WEB device is a “one-and-done” type treatment, overcoming the challenges of using multiple devices when treating aneurysms. The tiny basket-like device is intended to treat complicated aneurysms and avoid the placement of a stent device. This is a wonderful option for patients who cannot be put on blood thinners, as other treatment options for this type of aneurysm often require that.
“Baylor St. Luke’s is committed to delivering the most effective treatment options to meet the needs of all neurological patients,” said Peter Kan, M.D., neurosurgeon, Baylor St. Luke’s. “This is an exciting piece of technology and a great treatment option for patients suffering from wide-necked bifurcation aneurysms. We are proud to be using this leading-edge technology.”
The neuroscience services department at Baylor St. Luke’s in Houston’s renowned Texas Medical Center welcomes the PulseRider as a new era in the treatment of complex brain aneurysms and is dedicated to the highest levels of neurological and neurosurgical care.